Revenue: As of FY2025 Q3, the actual value is USD 303.65 K.EPS: As of FY2025 Q3, the actual value is USD -6.25.EBIT: As of FY2025 Q3, the actual value is USD -1.769 M.<h3>Revenue</h3><ul><li>Three Months Ended September 30, 2025: $303,651</li><li>Three Months Ended September 30, 2024: $406,859</li><li>Nine Months Ended September 30, 2025: $511,775</li><li>Nine Months Ended September 30, 2024: $1,812,140</li></ul><h3>Cost of Revenue</h3><ul><li>Three Months Ended September 30, 2025: $34,757</li><li>Three Months Ended September 30, 2024: $301,445</li><li>Nine Months Ended September 30, 2025: $126,546</li><li>Nine Months Ended September 30, 2024: $1,417,010</li></ul><h3>Gross Profit</h3><ul><li>Three Months Ended September 30, 2025: $268,894</li><li>Three Months Ended September 30, 2024: $105,414</li><li>Nine Months Ended September 30, 2025: $385,229</li><li>Nine Months Ended September 30, 2024: $395,130</li></ul><h3>Selling, General and Administrative Expenses</h3><ul><li>Three Months Ended September 30, 2025: $2,341,347</li><li>Three Months Ended September 30, 2024: $2,641,916</li><li>Nine Months Ended September 30, 2025: $5,539,144</li><li>Nine Months Ended September 30, 2024: $8,599,642</li></ul><h3>Research and Development Expenses</h3><ul><li>Three Months Ended September 30, 2025: -$3,211</li><li>Three Months Ended September 30, 2024: $109,365</li><li>Nine Months Ended September 30, 2025: -$90,426</li><li>Nine Months Ended September 30, 2024: $154,649</li></ul><h3>Impairment of ENTADFI Assets</h3><ul><li>Nine Months Ended September 30, 2024: $3,530,716</li></ul><h3>Impairment of Goodwill</h3><ul><li>Three Months Ended September 30, 2025: $0</li><li>Three Months Ended September 30, 2024: $0</li><li>Nine Months Ended September 30, 2025: $11,512,000</li><li>Nine Months Ended September 30, 2024: $15,453,000</li></ul><h3>Loss from Operations</h3><ul><li>Three Months Ended September 30, 2025: -$2,069,242</li><li>Three Months Ended September 30, 2024: -$2,645,867</li><li>Nine Months Ended September 30, 2025: -$16,575,489</li><li>Nine Months Ended September 30, 2024: -$27,342,877</li></ul><h3>Other Income (Expense)</h3><ul><li>Three Months Ended September 30, 2025: -$6,714,460</li><li>Three Months Ended September 30, 2024: -$1,237,922</li><li>Nine Months Ended September 30, 2025: -$3,126,540</li><li>Nine Months Ended September 30, 2024: -$2,036,987</li></ul><h3>Net Loss</h3><ul><li>Three Months Ended September 30, 2025: -$8,783,702</li><li>Three Months Ended September 30, 2024: -$3,827,405</li><li>Nine Months Ended September 30, 2025: -$19,702,029</li><li>Nine Months Ended September 30, 2024: -$29,252,681</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: -$6,587,805 for the nine months ended September 30, 2025; -$9,578,169 for the nine months ended September 30, 2024</li><li>Net Cash Provided by (Used in) Investing Activities: $0 for the nine months ended September 30, 2025; -$24,597 for the nine months ended September 30, 2024</li><li>Net Cash Provided by Financing Activities: $7,905,978 for the nine months ended September 30, 2025; $5,440,310 for the nine months ended September 30, 2024</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focusing on the commercialization of Proclarix, an in vitro diagnostic test for prostate cancer, and expects to generate revenue from sales by 2027. The company plans to continue hiring additional personnel, operating as a public company, and obtaining, maintaining, expanding, and protecting its intellectual property portfolio.</li><li>Non-Core Business: The company has abandoned the commercialization of ENTADFI and is in the process of destroying its inventory of the product. The company is also focusing on cost reduction efforts, including headcount reductions and the termination of the pension plan.</li><li>Priority: The company intends to pursue additional equity or debt financing to support operations and strategic initiatives. However, there are currently no committed sources of financing, and there is no assurance that additional funding will be available on favorable terms, if at all.</li></ul>

Onconetix | 10-Q: FY2025 Q3 Revenue: USD 303.65 K